Intra-arterial Bevacizumab for Posterior Fossa Hemangioblastoma.

Abstract

Hemangioblastoma (HB) is a rare, highly vascularized, and benign central nervous system (CNS) tumor. This vascularity is due to a high degree of signaling by vascular endothelial growth factor (VEGF). Consequently, anti-VEGF agents, such as bevacizumab, have been postulated and shown in a few cases to be effective in treating these tumors when surgical therapy is not feasible. Additionally, selective intra-arterial (IA) administration of bevacizumab has shown promise in treating other cancers such as glioblastoma (GBM). Here, we present the case of a 60-year-old female with a symptomatic posterior fossa HB where embolization and surgery were not feasible due to tumor location. She underwent selective IA treatment with bevacizumab, which led to tumor stability and symptomatic improvement. Bevacizumab has been used intravenously (IV) as a treatment for HB, however, its efficacy has not been well-established. This case demonstrates the potential viability of selective bevacizumab in HB, as demonstrated by symptomatic improvement and decreased tumor size on MRI. Further research is needed to demonstrate the specific efficacy of IA bevacizumab for CNS HB when surgery or other treatment modalities are not viable options.

• Authors: Zachary Sokol, Ava Hoeft, David Kung, Neil Belman, Martin Oselkin
• Journal: Cureus (Cureus) Vol. 14 Issue 12 Pg. e32624 (Dec 2022) ISSN: 2168-8184 [Print] United States
• PMID: 36654589 (Publication Type: Case Reports)
• Copyright: Copyright © 2022, Sokol et al.